Top

Published in:

01-09-2010 | Letter to the Editor

RAD50 gene mutations are not likely a risk factor for breast cancer in Poland

Authors: Maria Mosor, Iwona Ziółkowska-Suchanek, Krzysztof Rożnowski, Marta Baranowska, Danuta Januszkiewicz-Lewandowska, Jerzy Nowak

Published in: Breast Cancer Research and Treatment | Issue 2/2010

Excerpt

To the Editor …

Tauchi H, Matsuura S, Kobayashi J, Sakamoto S, Komatsu K (2002) Nijmegen breakage syndrome gene, NBS1, and molecular links to factors for genome stability. Oncogene 21:8967–8980CrossRefPubMed

Assenmacher N, Hopfner KP (2004) MRE11/RAD50/NBS1: complex activities. Chromosoma 113:157–166CrossRefPubMed

Roznowski K, Januszkiewicz-Lewandowska D, Mosor M, Pernak M, Litwiniuk M, Nowak J (2008) I171V germline mutation in the NBS1 gene significantly increases risk of breast cancer. Breast Cancer Res Treat 110:343–348CrossRefPubMed

Ziółkowska I, Mosor M, Wierzbicka M, Rydzanicz M, Pernak-Schwarz M, Nowak J (2007) Increased risk of larynx cancer in heterozygous carriers of the I171V mutation of the NBS1 gene. Cancer Sci 98:1701–1705CrossRefPubMed

Nowak J, Mosor M, Ziółkowska I et al (2008) Heterozygous carriers of the I171V mutation of the NBS1 gene have a significantly increased risk of solid malignant tumors. Eur J Cancer 44:627–630CrossRefPubMed

Mosor M, Ziółkowska I, Pernak-Schwarz M, Januszkiewicz-Lewandowska D, Nowak J (2006) Association of the heterozygous germline I171V mutation of the NBS1 gene with childhood acute lymphoblastic leukemia. Leukemia 20:1454–1456CrossRefPubMed

Steffen J, Varon R, Mosor M, Maneva G, Maurer M, Stumm M, Nowakowska D, Rubach M, Kosakowska E, Ruka W, Nowecki Z, Rutkowski P, Demkow T, Sadowska M, Bidziński M, Gawrychowski K, Sperling K (2004) Increased cancer risk of heterozygotes with NBS1 germline mutations in Poland. Int J Cancer 111(1):67–71CrossRefPubMed

Steffen J, Nowakowska D, Niwińska A, Czapczak D, Kluska A, Piatkowska M, Wiśniewska A, Paszko Z (2006) Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland. Int J Cancer 119:472–475CrossRefPubMed

Cybulski C, Gorski B, Debniak T, Gliniewicz B, Mierzejewski M, Masojć B, Jakubowska A, Matyjasik J, Złowocka E, Sikorski A, Narod SA, Lubiński J (2004) NBS1 is a prostate cancer susceptibility gene. Cancer Res 64:1215–1219CrossRefPubMed

10.

Heikkinen K, Karppinen SM, Soini Y, Makinen M, Winqvist R (2003) Mutation screening of Mre11 complex genes: indication of RAD50 involvement in breast and ovarian cancer susceptibility. J Med Genet 40(12):e131CrossRefPubMed

11.

Heikkinen K, Rapakko K, Karppinen SM, Erkko H, Knuutila S, Lundan T, Mannermaa A, Borresen-Dale AL, Borg A, Barkardottir RB, Petrini J, Winqvist R (2006) RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis 27:1593–1599CrossRefPubMed

12.

Tommiska J, Seal S, Renwick A, Barfoot R, Baskcomb L, Jayatilake H, Bartkova J, Tallila J, Kaare M, Tamminen A, Heikkila P, Evans DG, Eccles D, Aittomaki K, Blomqvist C, Bartek J, Stratton MR, Nevanlinna H, Rahman N (2006) Evaluation of RAD50 in familial breast cancer predisposition. Int J Cancer 118:2911–2916CrossRefPubMed

13.

Uhrhammer N, Delort L, Bignon YJ (2009) Rad50 c.687delT does not contribute significantly to familial breast cancer in a French population. Cancer Epidemiol Biomarkers Prev 18:684–685CrossRefPubMed

14.

Cao AY, Hu Z, Yin WJ, Jin W, Shao ZM (2010) Some common mutations of RAD50 and NBS1 in western populations do not contribute significantly to Chinese non-BRCA1/2 hereditary breast cancer. Breast Cancer Res Treat 121:247–249CrossRefPubMed

Title: RAD50 gene mutations are not likely a risk factor for breast cancer in Poland
Authors: Maria Mosor
Iwona Ziółkowska-Suchanek
Krzysztof Rożnowski
Marta Baranowska
Danuta Januszkiewicz-Lewandowska
Jerzy Nowak
Publication date: 01-09-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-0992-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2010

Physical activity levels after treatment for breast cancer: one-year follow-up

Among women who experience a recurrence after postmastectomy radiation therapy irradiation is not associated with more aggressive local recurrence or reduced survival

Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial

Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase

Corticosteroid treatment and timing of surgery in idiopathic granulomatous mastitis confusing with breast carcinoma

TGFB1 L10P polymorphism is associated with breast cancer susceptibility: evidence from a meta-analysis involving 47,817 subjects

Keynote webinar | Spotlight on antibody–drug conjugates in cancer